AbbVie Inc. $ABBV Stock Sold by Cardinal Capital Management Inc.

17 Oct 2026, 10:33 by Jessica Moore · The Cerbat Gem

Cardinal Capital Management Inc. lowered its holdings in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 10.4% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 245,195 shares of the company’s stock after selling 28,524 shares during the quarter. AbbVie makes up 1.5% of Cardinal Capital Management Inc.’s holdings, making the stock its 21st largest position. Cardinal Capital Management Inc.’s holdings in AbbVie were worth $64,141,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of ABBV. James T. Borello RIA lifted its stake in AbbVie by 3.5% in the 3rd quarter. James T. Borello RIA now owns 1,192 shares of the company’s stock valued at $312,000 after buying an additional 40 shares in the last quarter. Cyr Financial Inc. boosted its holdings in AbbVie by 7.2% in the 3rd quarter. Cyr Financial Inc. now owns 6,223 shares of the company’s stock worth $1,628,000 after buying an additional 418 shares during the last quarter. Cyndeo Wealth Partners LLC increased its stake in AbbVie by 2.8% during the 3rd quarter. Cyndeo Wealth Partners LLC now owns 141,048 shares of the company’s stock worth $36,897,000 after buying an additional 3,837 shares in the last quarter. Eagle Bay Advisors LLC increased its stake in AbbVie by 2.2% during the 3rd quarter. Eagle Bay Advisors LLC now owns 8,494 shares of the company’s stock worth $2,222,000 after buying an additional 182 shares in the last quarter. Finally, Selective Wealth Management Inc. increased its stake in AbbVie by 53.4% during the 3rd quarter. Selective Wealth Management Inc. now owns 1,315 shares of the company’s stock worth $373,000 after buying an additional 458 shares in the last quarter. 70.23% of the stock is owned by institutional investors and hedge funds.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

Positive Sentiment: Positive Phase 3 cancer-trial results provided the most important company-specific catalyst. AbbVie and Genmab reported that epcoritamab plus R-CHOP significantly reduced the risk of disease progression or death in newly diagnosed diffuse large B-cell lymphoma, strengthening AbbVie’s oncology pipeline and potential long-term growth. What Does AbbVie (ABBV) 51% DLBCL Risk Reduction Mean For Its Oncology Push?
Positive Sentiment: Analyst and options-market confidence remains favorable. Erste Group Bank issued a positive earnings outlook, Royal Bank of Canada reaffirmed its Outperform rating, and traders purchased an unusually high volume of ABBV call options—signals of bullish expectations ahead of results. Erste Group Bank Issues Positive Outlook for AbbVie Earnings
Positive Sentiment: Investors continue to view AbbVie as attractively valued for a large-cap pharmaceutical company. Coverage highlights a forward P/E near 16.4, strong year-to-date performance, a durable dividend, and newer medicines growing fast enough to offset declining Humira revenue. AbbVie is Outperforming the Market this Year So Far. Is Its 16.4x Valuation Attractive?
Positive Sentiment: Sector rotation is helping the stock. Investors have been shifting toward defensive pharmaceutical companies as technology stocks weaken, pushing major drugmakers close to record highs. Big Pharma Stocks Close Near All-Time Highs
Neutral Sentiment: Investors are now looking ahead to AbbVie’s third-quarter earnings report, scheduled for October 30. The results and updated guidance will test whether recent pipeline momentum and newer-drug growth justify the stock’s rally. AbbVie’s Q3 2026 Earnings: What to Expect
Negative Sentiment: The primary risk remains the transition away from established blockbusters. AbbVie must prove that newer medicines can sustain earnings as mature products face competition, while its trailing valuation appears elevated despite a more reasonable forward multiple. AbbVie vs. Merck: Which Pharma Stock Offers Better Value?

AbbVie Price Performance

ABBV opened at $285.32 on Friday. The company’s 50 day simple moving average is $262.74 and its two-hundred day simple moving average is $239.22. AbbVie Inc. has a 1-year low of $190.75 and a 1-year high of $291.40. The firm has a market capitalization of $504.10 billion, a price-to-earnings ratio of 80.60, a price-to-earnings-growth ratio of 1.29 and a beta of 0.24.

AbbVie (NYSE:ABBV – Get Free Report) last posted its quarterly earnings results on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.61 by $0.04. The business had revenue of $16.99 billion during the quarter, compared to analyst estimates of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%. The business’s revenue was up 10.2% compared to the same quarter last year. During the same period in the prior year, the business earned $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, equities analysts anticipate that AbbVie Inc. will post 13.94 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be paid a dividend of $1.73 per share. The ex-dividend date of this dividend is Thursday, October 15th. This represents a $6.92 dividend on an annualized basis and a yield of 2.4%. AbbVie’s payout ratio is 195.48%.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the company. Morgan Stanley increased their target price on AbbVie from $296.00 to $310.00 and gave the company an “overweight” rating in a report on Wednesday, October 7th. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $280.00 price target on shares of AbbVie in a research note on Tuesday. BMO Capital Markets boosted their price target on AbbVie from $258.00 to $300.00 and gave the stock an “outperform” rating in a research report on Monday, July 13th. Leerink Partners increased their price objective on AbbVie from $245.00 to $279.00 and gave the company an “outperform” rating in a research note on Wednesday, August 5th. Finally, Wall Street Zen downgraded AbbVie from a “strong-buy” rating to a “buy” rating in a research note on Sunday, July 5th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $277.18.

Get Our Latest Stock Report on AbbVie

Insiders Place Their Bets

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the company’s stock in a transaction on Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the sale, the executive vice president directly owned 74,430 shares in the company, valued at $18,607,500. This represents a 30.53% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.06% of the company’s stock.

AbbVie Company Profile

(Free Report)

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.

The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.